Clinical Trial

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2023-05-24; most recent amendment 2026-07-01.
Status change: Recruiting → Active, Not Recruiting 2026-07-01
Status change: Not Yet Recruiting → Recruiting 2023-06-07
Trial Details
NCT Number NCT05887492
Lead Sponsor Tango Therapeutics, Inc.
Conditions Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer, Lung Adenocarcinoma
Enrollment 126 participants
Start Date 2023-06-12
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-06